https://orcid.org/0000-0002-1770-6160
References
- Nurden AT, Fiore M, Nurden P, Pillois X. Glanzmann thrombasthenia: a review of ITGA2B and ITGB3 defects with emphasis on variants, phenotypic variability, and mouse models. Blood. 2011;118(23):5996–6005. doi:10.1182/blood-2011-07-36563521917754
- Poon MC, Di Minno G, d’Oiron R, Zotz R. New insights into the treatment of Glanzmann thrombasthenia. Transfus Med Rev. 2016;30(2):92–99. doi:10.1016/j.tmrv.2016.01.00126968829
- Iqbal I, Farhan S, Ahmed N. Glanzmann thrombasthenia: a clinicopathological profile. J Coll Physicians Surg Pak. 2016;26(8):647–650. doi:239627539755
- Solh T, Botsford A, Solh M. Glanzmann’s thrombasthenia: pathogenesis, diagnosis, and current and emerging treatment options. J Blood Med. 2015;6:219–227. doi:10.2147/JBM.S7131926185478
- Nurden AT. Glanzmann thrombasthenia. Orphanet J Rare Dis. 2006;1:10. doi:10.1186/1750-1172-1-1016722529
- Nurden AT. Acquired Glanzmann thrombasthenia: from antibodies to anti-platelet drugs. Blood Rev. 2019;36:10–22. doi:10.1016/j.blre.2019.03.00431010659
- Zotz RB, Poon MC, Di Minno G, D’Oiron R. The international prospective Glanzmann thrombasthenia registry: pediatric treatment and outcomes. TH Open. 2019;3(3):e286–e294. doi:10.1055/s-0039-169665731523745
- Diz-Kucukkaya R. Inherited platelet disorders including Glanzmann thrombasthenia and Bernard-Soulier syndrome. Hematology Am Soc Hematol Educ Program. 2013;2013:268–275. doi:10.1182/asheducation-2013.1.26824319190
- Krause KA, Graham BC. Glanzmann thrombasthenia. StatPearls. Treasure Island (FL): StatPearls Publishing LLC.; 2019.
- Novo Nordisk Inc. NovoSeven®RT Package Insert. 2019.
- Novo Nordisk A/S. NovoSeven®RT Package Leaflet. 2019.
- Lee A, Poon MC. Inherited platelet functional disorders: general principles and practical aspects of management. Transfus Apher Sci. 2018;57(4):494–501. doi:10.1016/j.transci.2018.07.01030031712
- Rodeghiero F, Tosetto A, Abshire T, et al; on behalf of the ISTH/SSC Joint VWF and Perinatal/Pediatric Hemostasis Subcommittees Working Group. ISTH/SSC Bleeding Assessment Tool: a standardized questionnaire and a proposal for a new bleeding score for inherited bleeding disorders. J Thromb Haemost. 2010;8:2036–2065.
- Elbatarny M, Mollah S, Grabell J, et al. Normal range of bleeding scores for the ISTH-BAT: adult and pediatric data from the merging project. Haemophilia. 2014;20(6):831–835. doi:10.1111/hae.1250325196510
- Nava T, Rivard GE, Bonnefoy A. Challenges on the diagnostic approach of inherited platelet function disorders: is a paradigm change necessary? Platelets. 2018;29(2):148–155. doi:10.1080/09537104.2017.135691829090587
- Rajpurkar M, Croteau SE, Boggio L, Cooper DL. Thrombotic events with recombinant activated factor VII (rFVIIa) in approved indications are rare and associated with older age, cardiovascular disease, and concomitant use of activated prothrombin complex concentrates (aPCC). J Blood Med. 2019;10:335–340. doi:10.2147/JBM.S21957331572039
- Di Minno G, Coppola A, Di Minno MN, Poon MC. Glanzmann’s thrombasthenia (defective platelet integrin alphaIIb-beta3): proposals for management between evidence and open issues. Thromb Haemost. 2009;102(6):1157–1164. doi:10.1160/TH09-04-022519967146
- Bannow BS, Konkle BA. Inherited bleeding disorders in the obstetric patient. Transfus Med Rev. 2018;32(4):237–243. doi:10.1016/j.tmrv.2018.06.00330097224
- Wijemanne A, Watt-Coote I, Austin S. Glanzmann thrombasthenia in pregnancy: optimising maternal and fetal outcomes. Obstetric Med. 2016;9(4):169–170. doi:10.1177/1753495X16655021
- Chitlur M, Recht M, Rajpurkar M, et al. Unmet needs in diagnosis and treatment of Glanzmann’s Thrombasthenia (GT): perceptions of US hematologists and nurses. Blood. 2014;124(21):2179. doi:10.1182/blood.V124.21.2179.2179